Bepirovirsen

GSK's New Drug Functionally Cures Hepatitis B in Nearly 20% of Patients

In late-stage trials, GSK's experimental drug bepirovirsen achieved a functional cure for nearly one in five chronic hepatitis B patients, a first for the disease, according to Reuters .